Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Avelumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vaximm AG Announces Phase 2a Trial Results for Glioblastoma
    Vaximm AG Announces Phase 2a Trial Results for Glioblastoma

    26 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vaximm-ag-an-osr-company-announces-results-from-phase-2a-trial-of-vxm01-and-avelumab-combination-therapy-in-glioblastoma-302411928.html

    PR NEWSWIRE
    26 Mar 2025
    Share Share
    EMD`s Biologic Bavencio (Avelumab) Receives Suppl Approval in US
    EMD`s Biologic Bavencio (Avelumab) Receives Suppl Approval in US

    11 Oct 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761049

    FDA
    11 Oct 2024
    Share Share
    ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC
    ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC

    23 May 2024

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/asco-merck-kgaa-pfizers-bavencio-combo-misses-survival-mark-crowded-kidney-cancer-space

    Angus Liu FIERCE PHARMA
    23 May 2024
    Share Share
    Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo
    Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo

    15 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240515322041/en

    BUSINESSWIRE
    15 May 2024
    Share Share
    Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line
    Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line

    22 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240122986123/en

    BUSINESSWIRE
    22 Jan 2024
    Share Share
    Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
    Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights

    13 Dec 2023

    // REUTERS

    https://www.reuters.com/markets/deals/pfizer-gets-ok-43-bln-seagen-deal-after-donating-cancer-drug-rights-2023-12-12/

    REUTERS
    13 Dec 2023
    Share Share